Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients

Silva, Javier; Garcı́a, Vanesa; García, José M.; Peña, Cristina; Domínguez, Gemma; Díaz, Raquel; Lorenzo, Yolanda; Hurtado, Alicia; Sánchez, Antonio; Bonilla, Félix

doi:10.1186/bcr1760

Cited by 81 publications

(71 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The frequency of BMI-1 expression (25%) was lower than those found in other studies (43 -62%) (Kim et al, 2004;Arnes et al, 2008;Choi et al, 2009). Others have found different results, BMI-1 expression being associated with more aggressive tumours (Glinsky et al, 2005;Silva et al, 2007). In addition, Glinsky et al (2005) found that expression of a BMI-1-driven 11 gene signature was associated with risk of metastases in breast carcinoma.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: Putative breast cancer stem cells might express surface markers such as aldehyde dehydrogenase 1 (ALDH1) and BMI-1 proteins. The aim of this study was to explore the expression of these proteins in breast cancers from an African population and their associations with the basal-like phenotype (BLP) and other molecular characteristics. METHODS: We analysed 192 paraffin-embedded breast carcinoma samples by tissue microarrays and immunohistochemical methods. RESULTS: In total, 88 tumours (48%) expressed ALDH1, whereas 46 (25%) expressed BMI-1 protein. Expression of ALDH1 was associated with high histological grade (Po0.0005), high mitotic count (Po0.0005), high nuclear grade (Po0.0005), oestrogen receptor (ER) negativity (Po0.0005), progesterone receptor (PR) negativity (P ¼ 0.009), p53 expression (P ¼ 0.034), cytokeratin 5/6 positivity (P ¼ 0.008), epidermal growth factor receptor (EGFR) expression (P ¼ 0.015) and the BLP (Po0.0005), whereas it was inversely associated with BMI-1 staining (P ¼ 0.009). On the other hand, BMI-1 expression was associated with low histological grade (P ¼ 0.004) and ER positivity (P ¼ 0.001). CONCLUSION: There was a high prevalence of ALDH1 expression among breast carcinomas and associations with basal markers and features of aggressive tumours. Studies are required to elucidate the importance of these findings for improved understanding of breast cancer biology.

show abstract

Section: Discussionmentioning

confidence: 74%

“…Still, BMI-1 has been linked to mammary carcinogenesis in some previous studies (Dimri et al, 2002;Datta et al, 2007). Although some find BMI-1 expression to be associated with a favourable prognosis (Kim et al, 2004;Arnes et al, 2008;Choi et al, 2009), others have reported the opposite (Glinsky et al, 2005;Silva et al, 2007).…”

mentioning

confidence: 95%

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In breast cancer exRNAs have been documented by a number of research groups [63,[96][97][98]. We present the most documented studies on cell-free exRNAs and CTC associated RNAs.…”

Section: Extracellular Rnas and Ctcs Associated Rnas In Breast Cancermentioning

confidence: 99%

“…Over-expression of Bmi-1 is reported and correlated to poor clinical prognosis in solid tumors of breast [123], lung [124] and colon [125] cancers; to name but a few. Silva et al [98] investigated Bmi-1 mRNA expression in plasma of a cohort of patients presenting with various subtypes and stages of breast cancer. Bmi-1 mRNA was detected in 43.2% of breast cancer specimens and also in 55% of healthy controls.…”

Section: Bmi-1mentioning

confidence: 99%

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Friel

Corcoran

Crown

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement-which in itself may have detrimental effects in terms of stimulating cancer progression/metastases-minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.

show abstract

“…It has been demonstrated that overexpression of BMI-1 occurs in a variety of cancers, including several types of leukemia [4][5][6][7] and solid tumors such as non-small cell lung cancer, 8 mantle cell lymphomas, 9 colorectal cancer 10 and prostate cancer, 11 suggesting a role in tumor cell growth and survival. Recently, BMI-1 overexpression has been identified as a marker of poor prognosis and metastasis in breast cancer, 12 acute myeloid leukemia 13 and neuroblastoma. 14 Notably, BMI-1 is associated with both humoral and T-cell responses, [15][16][17] suggesting that it represents a novel family of tumor-associated antigens(TAAs) that might be a potential target for immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma

Tong¹,

Liu²,

Huang³

et al. 2008

Cancer Biology & Therapy

View full text Add to dashboard Cite

This manuscript has been published online, prior to printing.Once the issue is complete and page numbers have been assigned, the citation will change accordingly.BMI-1 is overexpressed in a variety of cancers, which can activate the immune system to produce antibodies in tumor tissues. In this study, we isolated phage expressing BMI-1 protein by screening of a mixture of nasopharyngeal carcinoma (NPC) cDNA T7 phage library and found that the antibody against BMI-1 was elevated in the sera from NPC patients. BMI-1 mRNA was overexpressed at different levels in seven NPC cell lines compared with normal nasopharyngeal epithelial cell line NP69. Histochemistry showed that patient sera were more reactive with BMI-1 than normal sera. Antibody affinity assay using sera from 40 NPC patients and 54 controls showed that BMI-1 antibody was significantly greater in patient sera than in normal controls (patient 0.791 ± 0.025 and normal 0.488 ± 0.042; p < 0.001) and the BMI-1 autoantibody be significantly related with the progress of NPC (Benign versus LNPC P = 0.001; LNPC versus MNPC p = 0.047). Analysis of the results with logistic regression and receiver operating characteristics (ROC) curves showed that BMI-1 antibody was a modest marker for NPC (sensitivity 0.74 and specificity 0.73; AUC = 0.8044). The showed that BMI-1 antibody as a potential marker of NPC may be rational, and could have diagnostic and prognostic value.

show abstract

Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients

Cited by 81 publications

References 32 publications

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma

Contact Info

Product

Resources

About